The effects of interferon α2b on chemically-induced peritoneal fibrosis and on peritoneal tissue MMP-2 and TIMP-2 levels in rats

Journal of International Medical Research

Volumn 38, Issue 1, 2010, Pages 187-194

  Ucar, Edip ^a   Borazan, A ^a   Semerci, E ^a   Binici, D N ^a   Yaldiz, M ^b   Aysal, A ^c   Altug, E ^b   Kuvandik, C ^d   Huzmeli, C ^a   Yetim, T ^a   Canda, S ^b  

^a Erzurum Education and Research Hospital ^*  (Turkey)

^b MUSTAFA KEMAL UNIVERSITY   (Turkey)

^c DOKUZ EYLUL UNIVERSITY   (Turkey)

^d Kirikhan Government Hospital   (Turkey)

Author keywords

Chlorhexidine gluconate; Interferon 2B (IFN 2B); Matrix metalloproteinase 2 (MMP 2); Parietal thickening; Peritoneal fibrosis; Rats; Tissue inhibitors of metalloproteinase 2 (TIMP 2)

Indexed keywords

ALCOHOL; CHLORHEXIDINE GLUCONATE; GELATINASE A; PEGINTERFERON ALPHA2B; SODIUM CHLORIDE; TISSUE INHIBITOR OF METALLOPROTEINASE 2; ALPHA2B INTERFERON; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; BIOLOGICAL MARKER; CHLORHEXIDINE; DRUG CARRIER; DRUG DERIVATIVE; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2B;

ABDOMINAL WALL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PERITONEUM; PROTEIN EXPRESSION; RAT; RETROPERITONEAL FIBROSIS; THICKNESS; TISSUE LEVEL; TREATMENT OUTCOME; TREATMENT RESPONSE; VASCULARIZATION; VASCULITIS; ANIMAL; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; ENZYMOLOGY; METABOLISM; PERITONEAL FIBROSIS; WISTAR RAT;

ANIMALS; ANTI-INFECTIVE AGENTS; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; CHLORHEXIDINE; DISEASE MODELS, ANIMAL; DRUG CARRIERS; INTERFERON ALFA-2B; MALE; MATRIX METALLOPROTEINASE 2; PERITONEAL FIBROSIS; PERITONEUM; POLYETHYLENE GLYCOLS; RATS; RATS, WISTAR; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 77749298704     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001003800121     Document Type: Article

References (17)

1. Krediet RT: 30 years of peritoneal dialysis development: the past and the future. Perit Dial Int 2007; 27(suppl 2): S35-S41.
2. Hirahara I, Inoue M, Okuda K, et al: The potential of matrix metalloproteinase-2 as a marker of peritoneal injury, increased solute transport, or progression to encapsulating peritoneal sclerosis during peritoneal dialysis - a multicentre study in Japan. Nephrol Dial Transplant 2007; 22: 560-567.
3. Margetts PJ, Bonniaud P: Basic mechanisms and clinical implications of peritoneal fibrosis. Perit Dial Int 2003; 23: 530-541.
4. Miyata T, Devuyst O, Kurokawa K, et al: Toward better dialysis compatibility: advances in the biochemistry and pathophysiology of the peritoneal membranes. Kidney Int 2002; 61: 375-386.
5. Williams JD, Craig KJ, Topley N, et al: Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002; 13: 470-479.
6. Hirahara I, Umeyama K, Shofuda KI, et al: Increase of matrix metalloproteinase-2 in dialysate of rat sclerosing encapsulating peritoneal model. Nephrology 2002; 7: 161-169.
7. Nagase H, Visse R, Murphy G: Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006; 69: 562-573.
8. Alvarez GC, Madrid-Marina V, Jimenez-Mendez R, et al: Combined therapy with danazol, pegilated interferon, and ribavirin improves thrombocytopenia and liver injury in rats with fibrosis. Ann Hepatol 2007; 6: 233-241.
9. Tanabe J, Izawa A, Takemi N, et al. Interferon-β reduces the mouse liver fibrosis induced by repeated administration of concanavalin A via the direct and indirect effects. Immunology 2007; 122: 562-570.
10. Ishii Y, Sawada T, Shimizu A, et al: An experimental sclerosing encapsulating peritonitis model in mice. Nephrol Dial Transplant 2001; 16: 1262-1266.
11. Sis B, Sarioglu S, Sokmen S, et al: Desmoplasia measured by computer assisted image analysis: an independent prognostic marker in colorectal carcinoma. J Clin Pathol 2005; 58: 32-38.
12. Ersoy R, Celik A, Yilmaz O, et al: The effects of irbesartan and spironolactone in prevention of peritoneal fibrosis in rats. Perit Dial Int 2007; 27: 424-431.
13. Junor BJR, Briggs JD, Forwell MA, et al: Sclerosing peritonitis - the contribution of chlorhexidine in alcohol. Perit Dial Bull 1985; 5: 101-104.
14. Martin J, Yung S, Robson RL, et al: Production and regulation of matrix metalloproteinases and their inhibitors by human peritoneal mesothelial cells. Perit Dial Int 2000; 20: 524-533.
15. Margetts PJ, Bonniaud P: Basic mechanisms and clinical implications of peritoneal fibrosis. Perit Dial Int 2003; 23: 530-541.
16. Dollery CM, McEwan JR, Henney AM: Matrix metalloproteinases and cardiovascular disease. Circ Res 1995; 77: 863-868.
17. Galis ZS, Khatri JJ: Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 2002; 90: 251-262.